Over the past two years, investigators from the Perelman School of Medicine at the University of Pennsylvania have reported results from a human trial in GBM using chimeric antigen receptor (CAR) T
cell therapy, through which patients» own T
cells were engineered to track down and
kill cancer
cells that
express a
tumor - specific protein known as EGFRvIII.